China (Mainland)
Premiumsupplier
Osimertinib Mesylate CAS 1421373-66-1 Osimertinib CAS NO.1421373-66-1
- Min.Order: 10 Gram
- Payment Terms: L/C,T/T,
- Product Details
Keywords
- 1421373-66-1
- Osimertinib
- Osimertinib Mesylate
Quick Details
- ProName: Osimertinib Mesylate CAS 1421373-66-1 ...
- CasNo: 1421373-66-1
- Molecular Formula: C12H14CL2FNO4S
- Appearance: white powder
- Application: Pharmaceutical raw materials
- DeliveryTime: as customers request
- PackAge: 1kg/2kg/5kg aluminum foil/tin, 25kg/dr...
- Port: any port in China
- ProductionCapacity: 500 Kilogram/Month
- Purity: >99%
- Storage: Cool Dry Place
- Transportation: BY SEA OR BY AIR
- LimitNum: 10 Gram
Superiority
| 1)Quick Response Within 12 hours; |
| 2)Quality Guarantee: All products are strictly tested by our QC, confirmed by QA and approved by third party lab in China, USA, Canada, Germany, UK, Italy, France etc. |
| 3) OEM/ODM Available; |
| 4) Reasonable & Competitive Price; |
| 5) Fast Delivery: Samples from stock; bulk products within 7 days; |
| 6) Professional Documents for Your Clearance; |
| 7) Economic Freight Save Your Cost; |
| 8) All your money be refund immediately if quality issue happens. |
Details
Osimertinib mesylate Basic information
Product Name: Osimertinib mesylate
Synonyms: AZD-9291 (Mesylate);N-[2-[[2-(Dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-2-propenamide methanesulfonate (1:1);AZD-9291 mesylate N-[2-[[2-(Dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-2-propenamide methanesulfonate (1:1);Osimertinib;N-[2-(2-dimethylaminoethylmethylamino)-4-methoxy-5-[[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino]phenyl]prop-2-enamide mesylate salt;Osimertinib Mesylate(AZD9291);Osimertinib mesylate;Mereletinib mesylate
CAS: 1421373-66-1
MF: C28H33N7O2.CH4O3S
MW: 595.71298
EINECS: 200-064-1
Product Categories: AZD09;API
Mol File: 1421373-66-1.mol
Osimertinib mesylate Structure
Osimertinib mesylate Chemical Properties
Description:
Osimertinib is active against exon 19 deletions, exon 21 mutations, and also the exon 20 T790M mutations. It is preferentially selective for mutated EGFR, and therefore toxicity at therapeutic doses is lower than for first- and second-generation agents. Notably, osimertinib is able to cross the blood-brain barrier, making it active against disease in the CNS.